Article
Multidisciplinary Sciences
Jiahui Xu, Xiaoli Yang, Qiaodan Deng, Cong Yang, Dong Wang, Guojuan Jiang, Xiaohong Yao, Xueyan He, Jiajun Ding, Jiankun Qiang, Juchuanli Tu, Rui Zhang, Qun-Ying Lei, Zhi-min Shao, Xiuwu Bian, Ronggui Hu, Lixing Zhang, Suling Liu
Summary: Enhanced neovasculogenesis, especially vasculogenic mimicry (VM), contributes to the development of triple-negative breast cancer (TNBC). We identified TEM8 as a functional marker for VM-forming BTICs in TNBC, providing a target for the development of effective therapies against TNBC targeting both BTIC self-renewal and neovasculogenesis simultaneously. TEM8 promotes stemness and VM differentiation capacity through a RhoC/ROCK1/SMAD5 axis.
NATURE COMMUNICATIONS
(2021)
Article
Cell Biology
Yu Zhang, Wanyu Wang, Jiali Min, Suosi Liu, Qianrong Wang, Yu Wang, Yang Xiao, Xia Li, Zhiguang Zhou, Shanshan Liu
Summary: The expression of ZNF451 is upregulated in triple-negative breast cancer (TNBC) and is associated with a poor prognosis. ZNF451 enhances TNBC progression by interacting with and enhancing the activity of the transcriptional activator SLUG. Disturbing the ZNF451-SLUG interaction can suppress TNBC progression by reducing CCL5 expression and counteracting the migration and activation of tumor-associated macrophages.
Article
Multidisciplinary Sciences
Nataliia Petruk, Sanni Tuominen, Malin Akerfelt, Jesse Mattsson, Jouko Sandholm, Matthias Nees, Gennady G. Yegutkin, Arja Jukkola, Johanna Tuomela, Katri S. Selander
Summary: Inhibition of CD73 significantly decreases cellular viability and migration in vitro, suppresses hypoxia-induced increase in viability, and prevents cell protrusion elongation in both normoxia and hypoxia. CD73 suppression also leads to decreased tumor growth and metastasis in vivo by maintaining a more epithelial phenotype.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Meng Yuan, Megan E. E. Barefoot, Kendell Peterson, Moray J. J. Campbell, Jan K. K. Blancato, Manjing Chen, Marcel O. O. Schmidt, Amber J. J. Kiliti, Hong-Bin Fang, Anton Wellstein, Anna T. T. Riegel, Ghada M. M. Sharif
Summary: Mutations in the ANKRD11/ANCO1 gene are implicated in neurodegenerative disorders and show loss of heterozygosity and low expression in certain cancers. This study demonstrates that low ANCO1 mRNA and protein expression levels are prognostic markers for poor clinical outcomes in breast cancer, particularly in the triple-negative subtype. Knockdown of ANCO1 in early-stage triple-negative breast cancer cells promotes aneuploidy, cellular senescence, and enhanced invasion. Loss of ANCO1 expression activates breast-cancer-specific enhancers and oncogenic pathways, accelerating the early-stage progression of breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Shengnan Sha, Luyi Si, Xinrui Wu, Yuanbiao Chen, Hui Xiong, Ying Xu, Wangrui Liu, Haijun Mei, Tao Wang, Mei Li
Summary: This study investigates the potential role of cuproptosis-related genes (CRGs) in the tumor microenvironment (TME) of triple-negative breast cancer (TNBC). The results show that CRGs are closely associated with tumor immunity in TNBC and can be used to evaluate tumor immune cell infiltration, clinical features, and prognosis. This research provides new directions for the development of novel drugs in the future.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Shao-Ying Yang, Yi-Fan Xie, Tai-Mei Zhang, Ling Deng, Li Liao, Shu-Yuan Hu, Yin-Ling Zhang, Fang-Lin Zhang, Da-Qiang Li
Summary: This study reports the upregulation of IMPA1 in TNBC and its role in proliferation, metastasis and tumor formation in TNBC cells. Transcriptome sequencing analysis reveals that IMPA1 induces mTOR activity and epithelial-mesenchymal transition (EMT) process, thus promoting TNBC progression.
Review
Biochemistry & Molecular Biology
Yang Liu, Yueting Hu, Jinqi Xue, Jingying Li, Jiang Yi, Jiawen Bu, Zhenyong Zhang, Peng Qiu, Xi Gu
Summary: Immunotherapy has emerged as a promising strategy for treating triple-negative breast cancer (TNBC), which stimulates the immune system to kill tumor cells and offers new hope for patients. Breakthroughs in immune checkpoint inhibitors (ICIs) have led to individualized immunotherapy schedules and the combination with other treatment methods to overcome drug resistance.
Article
Nutrition & Dietetics
Getinet M. Adinew, Equar Taka, Bereket Mochona, Ramesh B. Badisa, Elizabeth A. Mazzio, Rashid Elhag, Karam F. A. Soliman
Summary: The tumor microenvironment plays a crucial role in cancer research, particularly in the development and progression of breast cancer. Various cellular components in the microenvironment contribute to tumor promotion and uncontrolled cell proliferation through the release of pro-inflammatory molecules. Thymoquinone has potential for mitigating the microenvironment and could be used in the prevention and treatment of breast cancer.
Article
Oncology
Huicheng Liu, Lili Bai, Liu Huang, Na Ning, Lin Li, Yijia Li, Xuejiao Dong, Qiuyang Du, Minghui Xia, Yufei Chen, Likun Zhao, Yanhu Li, Qingwu Meng, Jing Wang, Yaqi Duan, Jie Ming, Andy Qingan Yuan, Xiang-Ping Yang
Summary: The study developed a bispecific antibody F7AK3 targeting TROP2 and CD3 antigens for TNBC, showing potential antitumor activity in vitro and in vivo by activating T cells against TNBC cells. Further preclinical and clinical evaluation of F7AK3 is warranted for advanced or metastatic TNBC patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Cell Biology
Anli Yang, Fu Peng, Lewei Zhu, Xing Li, Shunling Ou, Zhongying Huang, Song Wu, Cheng Peng, Peng Liu, Yanan Kong
Summary: Melatonin treatment downregulated FUNDC1 and lnc049808 in TNBC cell lines, which inhibited cell proliferation, invasion, and metastasis. lnc049808 and FUNDC1 acted as competing endogenous RNAs binding to miR-101, indicating a potential therapeutic pathway for TNBC progression inhibition by melatonin.
CELL DEATH & DISEASE
(2021)
Review
Genetics & Heredity
Sotiris Loizides, Anastasia Constantinidou
Summary: Triple negative breast cancer is a biologically diverse subtype of breast cancer with aggressive clinical behavior and poor prognosis. Recent studies have focused on understanding the complex genomic and biological profile of TNBC in order to develop personalized treatment strategies. The immune driven landscape associated with TNBC includes high immunogenicity, specific immune activation signatures, increased expression of immunosuppressive genes, and higher levels of stromal Tumor Infiltrating Lymphocytes. The unprecedented response of TNBC to immunotherapy has significantly changed the standard of care, but the relationship between immune infiltration and mutational signatures in TNBC is still not fully understood.
FRONTIERS IN GENETICS
(2023)
Article
Cell Biology
Liting Jin, Chenggang Luo, Xinhong Wu, Manxiu Li, Shun Wu, Yaojun Feng
Summary: The study revealed that HAGLR promotes the growth of TNBC through the miR-335-3p/WNT2 axis, and this was validated in in vivo tumorigenesis experiments.
Review
Immunology
Jie Li, Dejiao He, Sicheng Li, Jun Xiao, Zhanyong Zhu
Summary: This review discusses the role of ferroptosis in TNBC and explores its potential value in the progression, diagnosis, and treatment of TNBC.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Xiaoyuan Ji, Daoxia Guo, Jia Ma, Min Yin, Yun Yu, Chang Liu, Yanfeng Zhou, Jinli Sun, Qian Li, Nan Chen, Chunhai Fan, Haiyun Song
Summary: The hydrogel patch designed to modulate the plasticity of T-ICs in TNBC shows promising results in improving chemosensitivity, enhancing tumor immunogenicity, and increasing T-cell infiltration. Additionally, the patch efficiently suppresses tumor growth, postsurgical relapse, and metastasis with a single dose, demonstrating superior efficacy against multidrug resistance.
ADVANCED MATERIALS
(2021)
Article
Immunology
Nataliia Petruk, Arafat Siddiqui, Sina Tadayon, Jorma Maatta, Pieta K. Mattila, Arja Jukkola, Jouko Sandholm, Katri S. Selander
Summary: Bisphosphonates (BPs) are bone-protecting osteoclast inhibitors commonly used in the treatment of osteoporosis and skeletal complications of malignancies. In early breast cancer, adjuvant nitrogen-containing BPs have shown potential benefits, but there is a lack of biomarkers to predict response. This study investigates the mechanisms by which BPs exert their effects and identifies potential factors influencing their efficacy.
FRONTIERS IN IMMUNOLOGY
(2023)
